Offerings // LIFECORE BIOMEDICAL, INC. DE

LFCR offering history

Every offering-related filing in LIFECORE BIOMEDICAL, INC. DE’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 1,000 filings back to Apr 10, 2012.

Last executed offering

Oct 4, 2024

8-K — priced deal (shares or notes)

Last registration (announced)

Sep 23, 2025

S-3 — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Sep 30, 2025	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Sep 30, 2025	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Sep 23, 2025	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Oct 23, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Oct 22, 2024	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Oct 15, 2024	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Oct 10, 2024	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Oct 4, 2024	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Aug 29, 2024	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
May 22, 2024	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Jun 9, 2023	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Jun 9, 2023	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jun 6, 2023	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Apr 6, 2023	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Jan 10, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Nov 25, 2022	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Nov 2, 2015	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Oct 16, 2015	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet

LFCR offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full LFCR workspace →

LFCR offering FAQ

When did LFCR last execute an offering?

Per SEC filings, LIFECORE BIOMEDICAL, INC. DE's most recent priced offering document is a 8-K filed 2024-10-04. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did LFCR last announce or register an offering?

The most recent registration is a S-3 filed 2025-09-23. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.